Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-18.37M |
| Operating Margin | 0.00% |
| Return on Equity | -127.00% |
| Return on Assets | -62.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.78 |
| Price-to-Book | 0.41 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 2.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.28M |
| Float | $1.63M |
| % Insiders | 14.85% |
| % Institutions | 0.81% |
Volatility is currently expanding